Translate this page into:
Authors' Reply
Corresponding author: Dr. Neetu Bhari, Department of Dermatology and Venereology, All India institute of Medical Sciences, New Delhi, India. drntbhari@gmail.com
-
Received: ,
Accepted: ,
How to cite this article: Patra S, Senthilnathan G, Ramam M, Arava S, Bhari N. Authors' Reply. Indian J Dermatol Venereol Leprol 2022;88:213.
Sir,
We thank the correspondents1 for their interest in our article.2 We apologise for missing their article in our review of literature. While we agree with their comments, we could not plan treatment for our patient based on drug sensitivity as the organism did not grow in culture. We used empirical monotherapy with linezolid because she had failed combination treatment with amikacin, cotrimoxazole and doxycycline. The patient has not shown any recurrence after two years of follow-up.
Declaration of patient consent
The patient's consent is not required as the patient's identity is not disclosed or compromised.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
References
- A combination of trimethoprim/sulfamethoxazole with linezolid is useful for actinomycotic mycetoma: A summary of the existing data and the rationale of combination therapy. Indian J Dermatol Venereol Leprol. 2022;88:212-3.
- [Google Scholar]
- Linezolid: A novel treatment option for the treatment of a non-responsive case of actinomycotic mycetoma. Indian J Dermatol Venereol Leprol. 2021;87:455.
- [CrossRef] [PubMed] [Google Scholar]
